BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang K, Senthi S, Palma DA, Spoelstra FO, Warner A, Slotman BJ, Senan S. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiotherapy and Oncology 2013;109:51-7. [DOI: 10.1016/j.radonc.2013.06.047] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Rodríguez De Dios N, Navarro-Martin A, Cigarral C, Chicas-Sett R, García R, Garcia V, Gonzalez JA, Gonzalo S, Murcia-Mejía M, Robaina R, Sotoca A, Vallejo C, Valtueña G, Couñago F. GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer. World J Clin Oncol 2022; 13(4): 237-266 [DOI: 10.5306/wjco.v13.i4.237] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Murphy MC, Wrobel MM, Fisher DA, Cahalane AM, Fintelmann FJ. Update on Image-Guided Thermal Lung Ablation: Society Guidelines, Therapeutic Alternatives, and Postablation Imaging Findings. AJR Am J Roentgenol 2022. [PMID: 35319908 DOI: 10.2214/AJR.21.27099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Daly ME. Inoperable Early-Stage Non-Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy. J Clin Oncol 2022;40:539-45. [PMID: 34985921 DOI: 10.1200/JCO.21.01611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Lee K, Le T, Hau E, Hanna GG, Gee H, Vinod S, Dammak S, Palma D, Ong A, Yeghiaian-Alvandi R, Buck J, Lim R. A systematic review into the radiological features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non-small cell lung cancer (NSCLC): Local recurrence features of NSCLC post-SABR. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)03235-1. [PMID: 34879247 DOI: 10.1016/j.ijrobp.2021.11.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang Y, Li G, Li S, Wang Y, Zhao Y, Dong B, Wang J, Zhu R, Chen M. CT Appearance Pattern After Stereotactic Body Radiation Therapy Predicts Outcomes in Early-Stage Non-Small-Cell Lung Cancer. Front Oncol 2021;11:746785. [PMID: 34707992 DOI: 10.3389/fonc.2021.746785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hellbach K. [Modern tumor therapy and its pulmonary side effects]. Radiologe 2021;61:955-67. [PMID: 34550423 DOI: 10.1007/s00117-021-00912-5] [Reference Citation Analysis]
7 Guerreiro NFC, Araujo-Filho JAB, Horvat N, Lee HJ, Oliveira BSP, Ynoe de Moraes F, Castro I, Miranda Degrande FA, Abreu CEV, Giassi KS. Interobserver Variability in the Computed Tomography Assessment of Pulmonary Injury and Tumor Recurrence After Stereotactic Body Radiotherapy. J Thorac Imaging 2020;35:302-8. [PMID: 32168165 DOI: 10.1097/RTI.0000000000000495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ikawa T, Tabuchi T, Konishi K, Morimoto M, Hirata T, Kanayama N, Wada K, Toratani M, Okawa S, Ogawa K, Teshima T. Prolonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: A propensity score-weighted, single-center analysis. PLoS One 2021;16:e0253203. [PMID: 34143851 DOI: 10.1371/journal.pone.0253203] [Reference Citation Analysis]
9 Vlaskou Badra E, Baumgartl M, Fabiano S, Jongen A, Guckenberger M. Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research. Transl Lung Cancer Res 2021;10:1930-49. [PMID: 34012804 DOI: 10.21037/tlcr-20-860] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Dong B, Zhu X, Shu Z, Ji Y, Lu F, Wang J, Chen M. Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Body Radiotherapy Treatment for Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matching Analysis. Front Oncol 2020;10:585709. [PMID: 33244457 DOI: 10.3389/fonc.2020.585709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Dağdelen M, Akovalı ES, Barlas C, Can G, Dinçbaş FÖ. Interobserver agreement between interpretations of acute changes after lung stereotactic body radiotherapy. Strahlenther Onkol 2021;197:423-8. [PMID: 33231713 DOI: 10.1007/s00066-020-01711-y] [Reference Citation Analysis]
12 Kakino R, Nakamura M, Mitsuyoshi T, Shintani T, Kokubo M, Negoro Y, Fushiki M, Ogura M, Itasaka S, Yamauchi C, Otsu S, Sakamoto T, Sakamoto M, Araki N, Hirashima H, Adachi T, Matsuo Y, Mizowaki T. Application and limitation of radiomics approach to prognostic prediction for lung stereotactic body radiotherapy using breath-hold CT images with random survival forest: A multi-institutional study. Med Phys 2020;47:4634-43. [PMID: 32645224 DOI: 10.1002/mp.14380] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yang WC, Hsu FM, Yang PC. Precision radiotherapy for non-small cell lung cancer. J Biomed Sci 2020;27:82. [PMID: 32693792 DOI: 10.1186/s12929-020-00676-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
14 Chassagnon G, Martini K, Giraud P, Revel MP. Radiological assessment after stereotactic body radiation of lung tumours. Cancer Radiother 2020;24:379-87. [PMID: 32534799 DOI: 10.1016/j.canrad.2020.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Elbanna M, Shiue K, Edwards D, Cerra-Franco A, Agrawal N, Hinton J, Mereniuk T, Huang C, Ryan JL, Smith J, Aaron VD, Burney H, Zang Y, Holmes J, Langer M, Zellars R, Lautenschlaeger T. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy. Clin Lung Cancer 2021;22:e342-59. [PMID: 32736936 DOI: 10.1016/j.cllc.2020.05.024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Li Q, Liu Y, Su B, Zhao H, Lin Q, Zhu Y, Zhang L, Weng D, Gong X, Sun X, Xu Y. The CT appearance pattern of radiation-induced lung injury and tumor recurrence after stereotactic body radiation therapy in early stage non-small cell lung cancer. Transl Lung Cancer Res 2020;9:713-21. [PMID: 32676333 DOI: 10.21037/tlcr-20-609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Frerker B, Hildebrandt G. Distinguishing Radiation Pneumonitis from Local Tumour Recurrence Following SBRT for Lung Cancer

]]>. RMI 2020;Volume 13:1-23. [DOI: 10.2147/rmi.s176901] [Reference Citation Analysis]
18 Kim TH, Woo S, Halpenny DF, Kim YJ, Yoon SH, Suh CH. Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lung cancer? A systematic review and meta-analysis. Eur J Radiol 2020;127:108978. [PMID: 32298960 DOI: 10.1016/j.ejrad.2020.108978] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Yossi S, Nguyen D, Krhili S, Lizée T, Khodri M. [Prognosis factors after lung stereotactic body radiotherapy for non-small cell lung carcinoma]. Cancer Radiother 2020;24:267-74. [PMID: 32192839 DOI: 10.1016/j.canrad.2019.11.002] [Reference Citation Analysis]
20 Palma DA, Nguyen TK, Louie AV, Malthaner R, Fortin D, Rodrigues GB, Yaremko B, Laba J, Kwan K, Gaede S, Lee T, Ward A, Warner A, Inculet R. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. JAMA Oncol 2019;5:681-8. [PMID: 30789648 DOI: 10.1001/jamaoncol.2018.6993] [Cited by in Crossref: 22] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
21 Gouveia AG, Zalay OC, Chua KL, Moraes FY. Response evaluation after stereotactic ablative radiotherapy for localised non-small-cell lung cancer: an equipoise of available resource and accuracy. Br J Radiol 2020;93:20190647. [PMID: 31778312 DOI: 10.1259/bjr.20190647] [Reference Citation Analysis]
22 Mitchell KG, Nelson DB, Corsini EM, Correa AM, Erasmus JJ, Hofstetter WL, Mehran RJ, Roth JA, Swisher SG, Sepesi B, Walsh GL, Vaporciyan AA, Rice DC, Nguyen QN, Antonoff MB. Surveillance After Treatment of Non-Small-Cell Lung Cancer: A Call for Multidisciplinary Standardization. Innovations (Phila) 2020;15:57-65. [PMID: 31875755 DOI: 10.1177/1556984519886281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Zhang R, Wang C, Cui K, Chen Y, Sun F, Sun X, Xing L. Prognostic Role Of Computed Tomography Textural Features In Early-Stage Non-Small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy. Cancer Manag Res 2019;11:9921-30. [PMID: 31819630 DOI: 10.2147/CMAR.S220587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
24 Brooks ED, Verma V, Senan S, De Baere T, Lu S, Brunelli A, Chang JY; International Association for the Study of Lung Cancer Advanced Radiation Technology Committee. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. J Thorac Oncol 2020;15:176-89. [PMID: 31712134 DOI: 10.1016/j.jtho.2019.10.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
25 Halpenny D, O'Dwyer E, Camacho Vasquez J, Shaverdian N, Girshman J, Ginsberg MS. Imaging of Novel Oncologic Treatments in Lung Cancer Part 2: Local Ablative Therapies. J Thorac Imaging 2020;35:37-48. [PMID: 31592831 DOI: 10.1097/RTI.0000000000000452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Munoz-schuffenegger P, Kandel S, Alibhai Z, Hope A, Bezjak A, Sun A, Simeonov A, Cho B, Giuliani M. A Prospective Study of Magnetic Resonance Imaging Assessment of Post-radiation Changes Following Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer. Clinical Oncology 2019;31:720-7. [DOI: 10.1016/j.clon.2019.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Roy SF, Louie AV, Liberman M, Wong P, Bahig H. Pathologic response after modern radiotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2019;8:S124-34. [PMID: 31673516 DOI: 10.21037/tlcr.2019.09.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
28 Dubaere E, Goffaux M, Wanet M, Bihin B, Gheldof C, Demoulin AS, Bolly A, Bustin F, Duplaquet F, Baugnee PE, Gustin M, Hers V, Maisin F, Marchand E, Ocak S, Pirard L, Vancutsem O, Van Neck E, Vandermoten G, Zaharia L, Remouchamps V. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer. BMC Cancer 2019;19:639. [PMID: 31253136 DOI: 10.1186/s12885-019-5863-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
29 Mutsaers A, Chen H, Louie AV. Stereotactic ablative radiation therapy in lung cancer: an emerging standard. Curr Opin Pulm Med 2018;24:335-42. [PMID: 29521657 DOI: 10.1097/MCP.0000000000000482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Li H, Verma V, Brooks ED, Feng L, Zhang T, Welsh JW, Lin SH, Gomez D, Gandhi S, Heymach JV, Chang JY. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. Clin Lung Cancer 2019;20:e480-8. [PMID: 31078421 DOI: 10.1016/j.cllc.2019.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vanevski M, Rezo A, Elder C, Skala M, Wirth A, Wheeler G, Lim A, Shaw M, Schofield P, Irving L, Solomon B; TROG 09.02 CHISEL investigators. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2019;20:494-503. [PMID: 30770291 DOI: 10.1016/S1470-2045(18)30896-9] [Cited by in Crossref: 159] [Cited by in F6Publishing: 211] [Article Influence: 53.0] [Reference Citation Analysis]
32 Dosani M, Yang R, McLay M, Wilson D, Liu M, Yong-Hing CJ, Hamm J, Lund CR, Olson R, Schellenberg D. Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy. Curr Oncol 2019;26:e57-63. [PMID: 30853810 DOI: 10.3747/co.26.4167] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
33 He B, Zhao W, Pi JY, Han D, Jiang YM, Zhang ZG, Zhao W. A biomarker basing on radiomics for the prediction of overall survival in non-small cell lung cancer patients. Respir Res 2018;19:199. [PMID: 30305102 DOI: 10.1186/s12931-018-0887-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
34 Febbo JA, Gaddikeri RS, Shah PN. Stereotactic Body Radiation Therapy for Early-Stage Non–Small Cell Lung Cancer: A Primer for Radiologists. RadioGraphics 2018;38:1312-36. [DOI: 10.1148/rg.2018170155] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
35 Chen H, Tikkanen J, Boldt RG, Louie AV. Stereotactic ablative radiotherapy for early-stage lung cancer following double lung transplantation. Radiat Oncol 2018;13:142. [PMID: 30086765 DOI: 10.1186/s13014-018-1089-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
36 Frick MA, Kao GD, Aguarin L, Chinniah C, Swisher-McClure S, Berman AT, Levin WP, Cengel KA, DeCesaris C, Hahn SM, Dorsey JF, Simone CB 2nd. Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study. Int J Radiat Oncol Biol Phys 2018;102:536-42. [PMID: 30244877 DOI: 10.1016/j.ijrobp.2018.06.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
37 Shiue K, Cerra-Franco A, Shapiro R, Estabrook N, Mannina EM, Deig CR, Althouse S, Liu S, Wan J, Zang Y, Agrawal N, Ioannides P, Liu Y, Zhang C, DesRosiers C, Bartlett G, Ewing M, Langer MP, Watson G, Zellars R, Kong FM, Lautenschlaeger T. Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol 2018;13:1549-59. [PMID: 29959060 DOI: 10.1016/j.jtho.2018.06.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
38 Ronden MI, Palma D, Slotman BJ, Senan S. Brief Report on Radiological Changes following Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Lung Tumors: A Pictorial Essay. Journal of Thoracic Oncology 2018;13:855-62. [DOI: 10.1016/j.jtho.2018.02.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
39 Nguyen TK, Senan S, Bradley JD, Franks K, Giuliani M, Guckenberger M, Landis M, Loo BW, Louie AV, Onishi H, Schmidt H, Timmerman R, Videtic GM, Palma DA. Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study. Practical Radiation Oncology 2018;8:e71-8. [DOI: 10.1016/j.prro.2017.10.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
40 Senan S, Rusthoven CG, Slotman BJ, Siva S. Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017. J Thorac Oncol 2018;13:488-96. [PMID: 29452269 DOI: 10.1016/j.jtho.2018.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
41 Dyer BA, Daly ME. Surveillance imaging following definitive radiotherapy for non-small cell lung cancer: What is the clinical impact? Semin Oncol 2017;44:303-9. [PMID: 29580432 DOI: 10.1053/j.seminoncol.2018.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Choi JI. Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes. Transl Lung Cancer Res 2019;8:32-47. [PMID: 30788233 DOI: 10.21037/tlcr.2018.06.11] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
43 Shintani T, Matsuo Y, Iizuka Y, Mitsuyoshi T, Mizowaki T. A Retrospective Long-term Follow-up Study of Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer From a Single Institution: Incidence of Late Local Recurrence. Int J Radiat Oncol Biol Phys 2018;100:1228-36. [PMID: 29722662 DOI: 10.1016/j.ijrobp.2018.01.050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
44 Wang HH, Wu ZQ, Qian D, Zaorsky NG, Qiu MH, Cheng JJ, Jiang C, Wang J, Zeng XL, Liu CL, Tian LJ, Ying GG, Meng MB, Hao XS, Yuan ZY. Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis In Vitro and In Vivo. Int J Radiat Oncol Biol Phys 2018;101:49-62. [PMID: 29619976 DOI: 10.1016/j.ijrobp.2018.01.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
45 Ronden M, van Sörnsen de Koste J, Johnson C, Slotman B, Spoelstra F, Haasbeek C, Blom G, Bongers E, Warner A, Ward A, Palma D, Senan S. Incidence of High-Risk Radiologic Features in Patients Without Local Recurrence After Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 2018;100:115-21. [DOI: 10.1016/j.ijrobp.2017.09.035] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
46 MacManus M, Everitt S, Schimek-Jasch T, Li XA, Nestle U, Kong FS. Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization. Transl Lung Cancer Res 2017;6:670-88. [PMID: 29218270 DOI: 10.21037/tlcr.2017.09.05] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
47 Frakulli R, Salvi F, Balestrini D, Palombarini M, Akshija I, Cammelli S, Morganti AG, Zompatori M, Frezza G. Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2017;6:S1-7. [PMID: 29299403 DOI: 10.21037/tlcr.2017.10.01] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
48 Li Q, Kim J, Balagurunathan Y, Qi J, Liu Y, Latifi K, Moros EG, Schabath MB, Ye Z, Gillies RJ, Dilling TJ. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy. Radiat Oncol 2017;12:158. [PMID: 28946909 DOI: 10.1186/s13014-017-0892-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
49 Hörner-Rieber J, Dern J, Bernhardt D, König L, Adeberg S, Verma V, Paul A, Kappes J, Hoffmann H, Debus J, Heussel CP, Rieken S. Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer-Experiences from a Single Institution. Front Oncol 2017;7:215. [PMID: 28975083 DOI: 10.3389/fonc.2017.00215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
50 Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J, Escriu C, Peters S. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2017;28:iv1-iv21. [DOI: 10.1093/annonc/mdx222] [Cited by in Crossref: 538] [Cited by in F6Publishing: 764] [Article Influence: 107.6] [Reference Citation Analysis]
51 Shintani T, Matsuo Y, Iizuka Y, Mitsuyoshi T, Umeoka S, Nakamoto Y, Mizowaki T, Togashi K, Hiraoka M. Assessment of treatment response after lung stereotactic body radiotherapy using diffusion weighted magnetic resonance imaging and positron emission tomography: A pilot study. European Journal of Radiology 2017;92:58-63. [DOI: 10.1016/j.ejrad.2017.04.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
52 Li Q, Kim J, Balagurunathan Y, Liu Y, Latifi K, Stringfield O, Garcia A, Moros EG, Dilling TJ, Schabath MB, Ye Z, Gillies RJ. Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy. Med Phys. 2017;44:4341-4349. [PMID: 28464316 DOI: 10.1002/mp.12309] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
53 Jumeau R, Filion É, Bahig H, Vu T, Lambert L, Roberge D, Doucet R, Campeau MP. A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC. Br J Radiol 2017;90:20170196. [PMID: 28590814 DOI: 10.1259/bjr.20170196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
54 Murray P, Franks K, Hanna GG. A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer. Br J Radiol 2017;90:20160732. [PMID: 27885858 DOI: 10.1259/bjr.20160732] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 7.6] [Reference Citation Analysis]
55 Larue RT, Defraene G, De Ruysscher D, Lambin P, van Elmpt W. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. Br J Radiol. 2017;90:20160665. [PMID: 27936886 DOI: 10.1259/bjr.20160665] [Cited by in Crossref: 173] [Cited by in F6Publishing: 182] [Article Influence: 28.8] [Reference Citation Analysis]
56 Nguyen TK, Palma DA. Pros: After stereotactic ablative radiotherapy for a peripheral early-stage non-small cell lung cancer, radiological suspicion of a local recurrence can be sufficient indication to proceed to salvage therapy. Transl Lung Cancer Res 2016;5:647-50. [PMID: 28151535 DOI: 10.21037/tlcr.2016.12.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 Jumeau R, Bahig H, Filion É, Campeau MP, Lambert L, Roberge D, Gorgos AB, Vu T. Assessing the Need for Adjuvant Chemotherapy After Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Carcinoma. Cureus 2016;8:e901. [PMID: 28070470 DOI: 10.7759/cureus.901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Verstegen NE, Maat AP, Lagerwaard FJ, Paul MA, Versteegh MI, Joosten JJ, Lastdrager W, Smit EF, Slotman BJ, Nuyttens JJ, Senan S. Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer. Radiat Oncol 2016;11:131. [PMID: 27716240 DOI: 10.1186/s13014-016-0706-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
59 Rieber J, Abbassi-Senger N, Adebahr S, Andratschke N, Blanck O, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Lohr F, Petersen C, Schrade E, Streblow J, Uhlmann L, Wittig A, Sterzing F, Guckenberger M. Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. Int J Radiat Oncol Biol Phys. 2017;98:511-520. [PMID: 27843031 DOI: 10.1016/j.ijrobp.2016.09.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
60 Baker S, Dahele M, Lagerwaard FJ, Senan S. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol 2016;11:115. [PMID: 27600665 DOI: 10.1186/s13014-016-0693-8] [Cited by in Crossref: 75] [Cited by in F6Publishing: 87] [Article Influence: 12.5] [Reference Citation Analysis]
61 Peulen H, Mantel F, Guckenberger M, Belderbos J, Werner-wasik M, Hope A, Giuliani M, Grills I, Sonke J. Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 2016;96:134-41. [DOI: 10.1016/j.ijrobp.2016.04.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
62 Ghaye B, Wanet M, El Hajjam M. Imaging after radiation therapy of thoracic tumors. Diagn Interv Imaging 2016;97:1037-52. [PMID: 27567554 DOI: 10.1016/j.diii.2016.06.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
63 Mattonen SA, Ward AD, Palma DA. Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply? Br J Radiol 2016;89:20160113. [PMID: 27245137 DOI: 10.1259/bjr.20160113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
64 Bashir U, Siddique MM, Mclean E, Goh V, Cook GJ. Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges. AJR Am J Roentgenol 2016;207:534-43. [PMID: 27305342 DOI: 10.2214/AJR.15.15864] [Cited by in Crossref: 76] [Cited by in F6Publishing: 87] [Article Influence: 12.7] [Reference Citation Analysis]
65 Lee SU, Moon SH, Cho KH, Pyo HR, Kim JY, Kim DY, Kim TH, Suh YG, Kim YJ. Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas : Ablative dose PBT for NSCLC. Strahlenther Onkol 2016;192:649-57. [PMID: 27282279 DOI: 10.1007/s00066-016-0985-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
66 Mattonen SA, Palma DA, Johnson C, Louie AV, Landis M, Rodrigues G, Chan I, Etemad-rezai R, Yeung TP, Senan S, Ward AD. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment. International Journal of Radiation Oncology*Biology*Physics 2016;94:1121-8. [DOI: 10.1016/j.ijrobp.2015.12.369] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 14.0] [Reference Citation Analysis]
67 Huang K, Palma DA; IASLC Advanced Radiation Technology Committee. Follow-up of patients after stereotactic radiation for lung cancer: a primer for the nonradiation oncologist. J Thorac Oncol 2015;10:412-9. [PMID: 25695219 DOI: 10.1097/JTO.0000000000000435] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
68 Takenaka R, Shibamoto Y, Miyakawa A, Hashizume C, Baba F. The Fate of Residual Tumor Masses That Persist After Stereotactic Body Radiotherapy for Solitary Lung Nodules: Will They Recur? Clin Lung Cancer 2016;17:406-11. [PMID: 26781347 DOI: 10.1016/j.cllc.2015.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
69 Ricardi U, Badellino S, Filippi AR. Stereotactic body radiotherapy for early stage lung cancer: History and updated role. Lung Cancer 2015;90:388-96. [DOI: 10.1016/j.lungcan.2015.10.016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
70 Mattonen SA, Tetar S, Palma DA, Louie AV, Senan S, Ward AD. Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy. J Med Imaging (Bellingham) 2015;2:041010. [PMID: 26835492 DOI: 10.1117/1.JMI.2.4.041010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
71 Hamaji M, Chen F, Matsuo Y, Ueki N, Hiraoka M, Date H. Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 2015;10:1616-24. [DOI: 10.1097/jto.0000000000000662] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
72 Waissi W, Noël G, Giraud P. Surveillance après radiothérapie stéréotaxique des tumeurs pulmonaires. Cancer/Radiothérapie 2015;19:566-72. [DOI: 10.1016/j.canrad.2015.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
73 Verstegen NE, Lagerwaard FJ, Hashemi SM, Dahele M, Slotman BJ, Senan S. Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy. Journal of Thoracic Oncology 2015;10:1195-200. [DOI: 10.1097/jto.0000000000000576] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
74 Ricardi U, Badellino S, Filippi AR. Stereotactic radiotherapy for early stage non-small cell lung cancer. Radiat Oncol J 2015;33:57-65. [PMID: 26157674 DOI: 10.3857/roj.2015.33.2.57] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
75 Raziee H, Hope A, Faruqi S, Yap ML, Roberts H, Kandel S, Le LW, Brade A, Cho J, Sun A, Bezjak A, Giuliani ME. Classification and Reporting of Late Radiographic Changes After Lung Stereotactic Body Radiotherapy: Proposing a New System. Clin Lung Cancer 2015;16:e245-51. [PMID: 26077096 DOI: 10.1016/j.cllc.2015.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
76 Franks K, Jain P, Snee M. Stereotactic Ablative Body Radiotherapy for Lung Cancer. Clinical Oncology 2015;27:280-9. [DOI: 10.1016/j.clon.2015.01.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
77 Siva S, Callahan JW, Kron T, Chesson B, Barnett SA, Macmanus MP, Hicks RJ, Ball DL. Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases. Acta Oncol 2015;54:1105-12. [PMID: 25833329 DOI: 10.3109/0284186X.2015.1027409] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
78 Lindberg K, Nyman J, Riesenfeld Källskog V, Hoyer M, Lund JÅ, Lax I, Wersäll P, Karlsson K, Friesland S, Lewensohn R. Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience. Acta Oncol 2015;54:1096-104. [PMID: 25813471 DOI: 10.3109/0284186X.2015.1020966] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
79 Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: Controversies, insights, and changing horizons. Radiotherapy and Oncology 2015;114:138-47. [DOI: 10.1016/j.radonc.2014.11.036] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 10.3] [Reference Citation Analysis]
80 Sawyer B, Pun E, Samuel M, Tay H, Kron T, Bressel M, Ball D, Siva S. CT perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy. J Med Imaging Radiat Oncol 2015;59:207-15. [PMID: 25601133 DOI: 10.1111/1754-9485.12272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
81 Chehade S, Palma DA. Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions. Rep Pract Oncol Radiother 2015;20:403-10. [PMID: 26696779 DOI: 10.1016/j.rpor.2014.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
82 Vulquin N, Feutray S, Peignaux-casasnovas K, Humbert O, Créhange G, Truc G, Maingon P, Martin É. Évaluation radiologique de la réponse tumorale après radiothérapie pulmonaire en conditions stéréotaxiques. Cancer/Radiothérapie 2014;18:414-9. [DOI: 10.1016/j.canrad.2014.07.157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
83 Rwigema JM, Chen AM, Wang P, Lee JM, Garon E, Lee P. Incidental Mediastinal Dose Does Not Explain Low Mediastinal Node Recurrence Rates in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiotherapy. Clinical Lung Cancer 2014;15:287-93. [DOI: 10.1016/j.cllc.2014.01.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
84 Mattonen SA, Huang K, Ward AD, Senan S, Palma DA. New techniques for assessing response after hypofractionated radiotherapy for lung cancer. J Thorac Dis 2014;6:375-86. [PMID: 24688782 DOI: 10.3978/j.issn.2072-1439.2013.11.09] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
85 Peulen H, Belderbos J, Rossi M, Sonke J. Mid-ventilation based PTV margins in Stereotactic Body Radiotherapy (SBRT): A clinical evaluation. Radiotherapy and Oncology 2014;110:511-6. [DOI: 10.1016/j.radonc.2014.01.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]